{"id":1386,"date":"2012-07-23T19:05:50","date_gmt":"2012-07-23T23:05:50","guid":{"rendered":"https:\/\/cablemanpro.com\/wallstreetpr\/?p=1386"},"modified":"2012-07-23T22:54:01","modified_gmt":"2012-07-24T02:54:01","slug":"brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli","status":"publish","type":"post","link":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386","title":{"rendered":"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI)"},"content":{"rendered":"

Clinical trials for a stem cell therapy developed by Brainstorm Cell Therapeutics (OTC: BCLI)\u00a0showed promising results<\/a> in a patient\u2019s ability to tolerate the transplantation of their own cells. Buyers of the stock seemed unimpressed with the news as they failed to push the stock higher, even though the number of shares traded on the day topped the average daily volume by a multiple of six. Part of the trial was to evaluate the safety and preliminary efficacy of the company\u2019s bone-marrow-derived cell therapy, known as NurOwn.<\/p>\n

Shares of Brainstorm Cell Therapeutics closed Monday\u2019s trading session at $0.27, or down two cents from the final print on Friday. The stock opened near the day\u2019s high of $0.33, but steadily retreated throughout the day. In the final hour, the stock hit its low for the day of nearly $.025 before rallying a bit into the closing bell. Over 3.2 million shares traded, which made Monday one of the heaviest volume days in the last 12 months. Interestingly, half of the shares were traded in the first 30 minutes of the session.<\/p>\n

Like many biotechnology stocks, Brainstorm Cell Therapeutics’ share price can see wide swings related to news and commentary. The 52-week high trade for the stock happened almost a year ago at just a tick below $0.54. By the time the calendar changed to 2012, Brainstorm shares hit a low-water mark of $0.20, or seven cents below today\u2019s closing price. Recently, buyers seem more receptive to the stock as share prices made several passes at $0.35 in the last couple of weeks. The positive energy began during the latter part of June and the first week of July when the\u00a0company announced<\/a>\u00a0that\u00a0a patient receiving NurOwn treatment noticed marked improvement in speech, walking, balance and appetite. Was today’s price action really a yawn, or just a pause that refreshes after a few positive weeks?<\/p>\n

In other recent headlines, Brainstorm Cell Therapeutics announced on July 19, 2012, the closing of a secondary offering<\/a> of 19.8 million shares, plus warrants for an additional 14.8 million shares, at a price of $0.29. The offering fetched gross proceeds of $5.7 million.<\/p>\n

A check of Stockpromoters.com<\/a> shows a total of 23 promotions. The most recent letter touting the stock was printed over a year ago.\u00a0Brainstorm Cell Therapeutics received some attention today on\u00a0Twitter. InvestorStemCell.com<\/a> took note of the trial news, as did IQStockAlerts<\/a>.<\/p>\n

Brainstorm Cell Therapeutics is a biotechnology company focused on the development of stem cell therapies for neurodegenerative disorders that include Parkinson\u2019s disease, Multiple Sclerosis, ALS, along with spinal cord injuries. The company is headquartered in New York with a subsidiary located in Israel.<\/p>\n","protected":false},"excerpt":{"rendered":"

Clinical trials for a stem cell therapy developed by Brainstorm Cell Therapeutics (OTC: BCLI)\u00a0showed promising results in a patient\u2019s ability to tolerate the transplantation of […]<\/p>\n","protected":false},"author":10,"featured_media":1407,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":{"twitter_2902945987_2902945987":""},"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[3],"tags":[153],"stock_ticker":[],"class_list":["post-1386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-small-cap-stock-news","tag-bcli","entry"],"acf":[],"yoast_head":"\nBrainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI) - Wall Street PR<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI) - Wall Street PR\" \/>\n<meta property=\"og:description\" content=\"Clinical trials for a stem cell therapy developed by Brainstorm Cell Therapeutics (OTC: BCLI)\u00a0showed promising results in a patient\u2019s ability to tolerate the transplantation of […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\" \/>\n<meta property=\"og:site_name\" content=\"Wall Street PR\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/WallStreetPR\/\" \/>\n<meta property=\"article:published_time\" content=\"2012-07-23T23:05:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2012-07-24T02:54:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png\" \/>\n\t<meta property=\"og:image:width\" content=\"589\" \/>\n\t<meta property=\"og:image:height\" content=\"377\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Alan Masterson\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Alan Masterson\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#article\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\"},\"author\":{\"name\":\"Alan Masterson\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\"},\"headline\":\"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI)\",\"datePublished\":\"2012-07-23T23:05:50+00:00\",\"dateModified\":\"2012-07-24T02:54:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\"},\"wordCount\":443,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png\",\"keywords\":[\"BCLI\"],\"articleSection\":[\"Small Cap Stock News\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\",\"name\":\"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI) - Wall Street PR\",\"isPartOf\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png\",\"datePublished\":\"2012-07-23T23:05:50+00:00\",\"dateModified\":\"2012-07-24T02:54:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png\",\"width\":589,\"height\":377},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#website\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"name\":\"Wall Street PR\",\"description\":\"Latest News From WallStreet\",\"publisher\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#organization\",\"name\":\"Wall Street PR\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"contentUrl\":\"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png\",\"width\":537,\"height\":70,\"caption\":\"Wall Street PR\"},\"image\":{\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/WallStreetPR\/\",\"https:\/\/x.com\/WallstreetPRs\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90\",\"name\":\"Alan Masterson\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g\",\"caption\":\"Alan Masterson\"},\"description\":\"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).\",\"sameAs\":[\"https:\/\/cablemanpro.com\/wallstreetpr\"],\"url\":\"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI) - Wall Street PR","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386","og_locale":"en_US","og_type":"article","og_title":"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI) - Wall Street PR","og_description":"Clinical trials for a stem cell therapy developed by Brainstorm Cell Therapeutics (OTC: BCLI)\u00a0showed promising results in a patient\u2019s ability to tolerate the transplantation of […]","og_url":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386","og_site_name":"Wall Street PR","article_publisher":"https:\/\/www.facebook.com\/WallStreetPR\/","article_published_time":"2012-07-23T23:05:50+00:00","article_modified_time":"2012-07-24T02:54:01+00:00","og_image":[{"width":589,"height":377,"url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png","type":"image\/png"}],"author":"Alan Masterson","twitter_misc":{"Written by":"Alan Masterson","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#article","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386"},"author":{"name":"Alan Masterson","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90"},"headline":"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI)","datePublished":"2012-07-23T23:05:50+00:00","dateModified":"2012-07-24T02:54:01+00:00","mainEntityOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386"},"wordCount":443,"commentCount":0,"publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png","keywords":["BCLI"],"articleSection":["Small Cap Stock News"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#respond"]}]},{"@type":"WebPage","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386","url":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386","name":"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI) - Wall Street PR","isPartOf":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage"},"thumbnailUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png","datePublished":"2012-07-23T23:05:50+00:00","dateModified":"2012-07-24T02:54:01+00:00","breadcrumb":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#primaryimage","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2012\/07\/Screen-Shot-2012-07-23-at-9.56.27-PM.png","width":589,"height":377},{"@type":"BreadcrumbList","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/brainstorm-cell-therapeutics-clinical-trial-greeted-with-a-yawn-bcli-1386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cablemanpro.com\/wallstreetpr\/"},{"@type":"ListItem","position":2,"name":"Brainstorm Cell Therapeutics Clinical Trial Greeted With a Yawn (BCLI)"}]},{"@type":"WebSite","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#website","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","name":"Wall Street PR","description":"Latest News From WallStreet","publisher":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cablemanpro.com\/wallstreetpr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#organization","name":"Wall Street PR","url":"https:\/\/cablemanpro.com\/wallstreetpr\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/","url":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","contentUrl":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-content\/uploads\/2019\/10\/brand-logo.png","width":537,"height":70,"caption":"Wall Street PR"},"image":{"@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/WallStreetPR\/","https:\/\/x.com\/WallstreetPRs"]},{"@type":"Person","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/e2af522c6015a6a581684f88e4c33c90","name":"Alan Masterson","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cablemanpro.com\/wallstreetpr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f09370963119b5d583d3dec68718fdaffc52a80c920398e0d1387fee0a33129e?s=96&d=mm&r=g","caption":"Alan Masterson"},"description":"Alan has over 25 years of trading experience in the U.S. equity markets. He began his career in finance working on a program trading desk specializing in over-the-counter stocks. His career progressed from that point to his current position as senior trader on an institutional trading desk. In the evenings, Alan teaches economics at a local community college. He has contributed articles to various publications over the last six years, including feature articles for an economics magazine and various financial blogs. You may contact Alan via his email (alanmasterson@cablemanpro.com) or his Google+ page (https:\/\/plus.google.com\/103338576216002376250).","sameAs":["https:\/\/cablemanpro.com\/wallstreetpr"],"url":"https:\/\/cablemanpro.com\/wallstreetpr\/author\/alan-masterson"}]}},"_links":{"self":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/1386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/comments?post=1386"}],"version-history":[{"count":0,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/posts\/1386\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media\/1407"}],"wp:attachment":[{"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/media?parent=1386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/categories?post=1386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/tags?post=1386"},{"taxonomy":"stock_ticker","embeddable":true,"href":"https:\/\/cablemanpro.com\/wallstreetpr\/wp-json\/wp\/v2\/stock_ticker?post=1386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}